Patents Assigned to Virginia Commonwealth University
  • Patent number: 11046830
    Abstract: A method of synthesizing aerogels and cross-linked aerogels in a single step and in a single pot without requiring any solvent exchange is described. Porous matrices are synthesized through a modification of hydrolysis condensation of alkoxides in which addition of water is minimized. The reaction occurs in an ethanol-water azeotrope mixture; the water in the azeotrope slowly hydrolyzes the alkoxide. Additionally, after gelation, the porous matrix is dried in supercritical ethanol rather than liquid CO2, which allows for elimination of solvent exchange steps. These modifications allow for the preparation of aerogel monoliths in any size in one step and in one pot and much faster than conventional procedures. In addition, the method provides for custom aerogel parts with large dimensions, as well as high volume fabrication of aerogels. The custom aerogel parts may be used in a variety of thermal insulation applications.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: June 29, 2021
    Assignee: Virginia Commonwealth University
    Inventor: Massimo Bertino
  • Publication number: 20210177776
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in the treatment of neuropathic pain.
    Type: Application
    Filed: February 8, 2021
    Publication date: June 17, 2021
    Applicants: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah SPIEGEL, Robert Elliot ZIPKIN, Jeffrey Kroll ADAMS
  • Publication number: 20210154202
    Abstract: Compounds, comprising a selective ?-blocker coupled to a PAMAM dendrimer via a flexible spacer, and compositions containing the compounds, are provided. Methods of making and using the compounds and compositions for the treatment of glaucoma and other maladies are also provided.
    Type: Application
    Filed: April 16, 2019
    Publication date: May 27, 2021
    Applicant: Virginia Commonwealth University
    Inventors: Michael LANCINA, Juan WANG, Hu YANG
  • Patent number: 10994130
    Abstract: An example device for repairing a nerve is described herein. The device can include a flexible carrier layer made of a biologic material, and a metallic support member including a plurality of micro-protrusions extending therefrom. The metallic support member can be at least partially integrated with the flexible carrier layer. Additionally, the flexible carrier layer can be configured to cover at least a portion of the nerve, and the micro-protrusions can be configured to attach to a superficial tissue of the nerve.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: May 4, 2021
    Assignees: BioCircuit Technologies, Inc., Virginia Commonwealth University
    Inventors: Isaac Perry Clements, Andrew Willsie, James David Ross, Alex Weidenbach, Jonathan Isaacs
  • Patent number: 10988481
    Abstract: Analogues of 6 ?/?-naltrexamine (NAQ) are provided. The analogues are selective, reversible antagonists of the mu opioid receptor (MOR) that exhibit good blood brain barrier penetration. The compounds are used in the treatment of opioid addiction and other diseases and conditions, including for the treatment of pain.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: April 27, 2021
    Assignee: Virginia Commonwealth University
    Inventors: Yan Zhang, Dana E. Selley, William Dewey, Hamid Abkarali
  • Patent number: 10969379
    Abstract: A bioelectrochemical sensor utilizing a nanoporous gold electrode. The bioelectrochemical sensor is suitable for measuring redox in biologic media while having increased resistance to biofouling as compared to conventional electrodes such as planar gold electrodes, due to greater exposed surface area of the three-dimensional ligature structure defining the nanopores. The nanopores have a pore size of 5-100 nm, preferably with an average pore size of less than 50 nm, and more preferably with an average pore size of less than 20 nm.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: April 6, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Virginia Commonwealth University
    Inventors: Rodney C. Daniels, Kevin R. Ward, Maryanne M. Collinson
  • Patent number: 10945971
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 16, 2021
    Assignees: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Patent number: 10875834
    Abstract: Prodrugs and derivatives of 5-hydoxymethyl-2-furfural (5-HMF) with protected or modified aldehyde and/or alcohol moieties are provided. The prodrugs or derivatives exhibit increased bioavailability, e.g. due to having extended half-lives in circulation. The drugs are therefore administered i) at lower doses and/or ii) less frequently than 5-HMF, while still maintaining the beneficial therapeutic effects of 5-HMF.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: December 29, 2020
    Assignees: Virginia Commonwealth University, The Children's Hospital of Philadelphia
    Inventors: Martin K. Safo, Guoyan Xu, Yan Zhang, Osheiza Abdulmalik
  • Publication number: 20200384135
    Abstract: Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter and astrocyte elevated gene 1 (AEG-1) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols, e.g. for imaging and/or treating spontaneous metastasis. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.
    Type: Application
    Filed: December 30, 2019
    Publication date: December 10, 2020
    Applicants: Virginia Commonwealth University, The Johns Hopkins University
    Inventors: Martin Gilbert Pomper, Hyo-eun Bhang, Paul Fisher
  • Patent number: 10858331
    Abstract: The invention provides new aromatic aldehyde compounds that have greater potency in increasing the affinity of Hb for oxygen, greater potency for preventing sickling, and additional pharmacologic properties that ameliorate other symptoms of SCD. The invention further provides methods for treating SCD by providing a subject having SCD with a compound according to the invention.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: December 8, 2020
    Assignee: Virginia Commonwealth University
    Inventors: Martin Safo, Yan Zhang, Jurgen Venitz, Richmond Danso-Danqua, Tanvi Deshpande
  • Patent number: 10849361
    Abstract: Provided herein is a device for measuring puff topography generated by a human user of a smoking device and methods for using the same. The device may be used for research on puffing behavior of tobacco product users in both clinical and non-clinical settings.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: December 1, 2020
    Assignees: Virginia Commonwealth University, American University of Beirut
    Inventors: Alan Shihadeh, Thomas Eissenberg
  • Patent number: 10842860
    Abstract: Anaplasma phagocytophilum surface protein AipA and/or fragments thereof which comprise an invasin domain are used in compositions suitable to elicit an immune response to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. AipA proteins and protein fragments or antibodies directed to AipA proteins and protein fragments are also used in diagnostic assays to detect exposure to and/or infection with Anaplasmatacaea. AipA and/or fragments thereof are also used for these purposes in combination with one or both of Asp14 and OmpA proteins and/or fragments thereof which comprise an invasin domain. Homologs of these proteins are also used in the compositions and assays.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: November 24, 2020
    Assignee: Virginia Commonwealth University
    Inventor: Jason Carlyon
  • Patent number: 10844089
    Abstract: The sulfated oxysterol 5-cholesten-3?, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: November 24, 2020
    Assignee: Virginia Commonwealth University
    Inventors: Shunlin Ren, William M. Pandak
  • Patent number: 10800751
    Abstract: The invention provides new aromatic aldehyde compounds that have greater potency in increasing the affinity of Hb for oxygen, greater potency for preventing sickling, and additional pharmacologic properties that ameliorate other symptoms of SCD. The invention further provides methods for treating SCD by providing a subject having SCD with a compound according to the invention.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: October 13, 2020
    Assignee: Virginia Commonwealth University
    Inventors: Martin Safo, Jurgen Venitz, Richmond Danso-Danquah, Tanvi Deshpande, Yan Zhang
  • Patent number: 10786180
    Abstract: A system and method for reducing intrafractional motion of a subject The system includes a subject user device, whereby the user device includes an image acquisition device configured to receive location marker information of the subject to provide location marking data of the subject. The system may also include a digital processor configured to: receive the location marking data and determine movement of the subject relative to the location marker information; and communicate feedback of the movement to the subject to help the subject reduce intrafractional motion.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 29, 2020
    Assignees: University of Virginia Patent Foundation, Virginia Commonwealth University Intellectual Property Foundation
    Inventors: Taeho Kim, Harang Ju, Siyong Kim
  • Patent number: 10786517
    Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: September 29, 2020
    Assignees: Durect Corporation, Virginia Commonwealth University
    Inventors: Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
  • Patent number: 10751494
    Abstract: Ventilator associated pneumonia (VAP) may be prevented in a patient, or its occurrence reduced in a population of patients, by using an anti-VAP device or an anti-VAP material such as an anti-VAP mouthpiece that absorbs secretions. By reducing the problem of bacterial-containing secretions that otherwise build up in the airway of, and elsewhere in, the intubated patient, VAP can be prevented from occurring in intubated patients, such as patients intubated with an endotracheal tube (ETT) or a nasogastric tube. Anti-VAP mouthpieces also are useable in non-intubated patients to maintain oral hygiene.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: August 25, 2020
    Assignee: Virginia Commonwealth University
    Inventors: Kevin R. Ward, Curtis N. Sessler, Mary Jo Grap, Laurence J. DiNardo, Bruce D. Spiess, Rao R. Ivatury, Cindy Munro
  • Patent number: 10744172
    Abstract: A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: August 18, 2020
    Assignee: Virginia Commonwealth University
    Inventors: Paul Fisher, Devanand Sarkar, Paul Dent
  • Patent number: 10736951
    Abstract: Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: August 11, 2020
    Assignee: Virginia Commonwealth University
    Inventor: Jason A. Carlyon
  • Patent number: 10730752
    Abstract: Methods for a facile, template free and one-step synthesis of nanoporous carbons by using a heterocyclic aromatic organic compound as a single source precursor of both carbon and nitrogen are described. The heterocyclic aromatic organic compound contains nitrogen in pyrrolic and/or pyridinic positions and is chemically activated with NaOH, KOH or ZnCl2 at high temperatures in a solid state mixture as a synthesis protocol to promote fine micropores during carbonization. Nanoporous carbons synthesized by these methods that have superior gas sorption/storage and energy storage properties are also described. The nanoporous carbons are useful as carbon sequestration agents and supercapacitors.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: August 4, 2020
    Assignee: Virginia Commonwealth University
    Inventors: Hani M. El-Kaderi, Babak Ashourirad